Review the procedural, technological, and commercial factors that have impacted the field of cancer risk evaluation for inherited cancer syndromes in the past 18 months. You’ll become familiar with the rapid expansion of commercial testing laboratories providing germline testing for hereditary cancer syndromes and the use of next-generation sequencing. Leave with an understanding of the complexities faced by clinicians when determining patient eligibility for genetic testing, with third-party payers now determining eligibility and directing testing service accessibility.
Objectives